World's Best Scientists 2026 revealed!
Giancarlo Pruneri

Giancarlo Pruneri

D-Index & Metrics

Medicine

D-Index
95
Citations
32693
World Ranking
10080
National Ranking
358

Giancarlo Pruneri publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Giancarlo Pruneri sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 539 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Giancarlo Pruneri D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Giancarlo Pruneri sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Giancarlo Pruneri is affiliated with the University of Milan in Italy and has contributed extensively to research in medicine, with a particular focus on cancer research and oncology. Their work spans disciplines closely related to biochemistry, genetics, and molecular biology.

The primary fields of study for Giancarlo Pruneri include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these broader categories, their subfields of study cover:

  • Cancer Research
  • Oncology
  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Pathology and Forensic Medicine

The main research topics for Giancarlo Pruneri encompass:

  • Cancer Genomics and Diagnostics
  • Breast Cancer Treatment Studies
  • Cancer Immunotherapy and Biomarkers
  • Genetic factors in colorectal cancer
  • HER2/EGFR in Cancer Research
  • Lung Cancer Treatments and Mutations
  • Advanced Breast Cancer Therapies

Notable recent papers authored or co-authored by Giancarlo Pruneri include:

  • "ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)" (2020), published in Annals of Oncology
  • "ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer" (2023), published in Annals of Oncology
  • "The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group" (2021), published in npj Breast Cancer
  • "The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice" (2020), published in The Journal of Pathology
  • "Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer" (2020), published in npj Breast Cancer

Giancarlo Pruneri has published regularly in several scientific journals that range across oncology and cancer biology topics. Frequent publication venues include:

  • Annals of Oncology
  • Cancer Research
  • ESMO Open
  • Journal of Clinical Oncology
  • Clinical Cancer Research

The scientist has collaborated extensively with multiple co-authors. Some of the most frequent co-authors are:

  • Andrea Vingiani
  • Filippo de Braud
  • Claudio Vernieri
  • Serena Di Cosimo
  • Luca Agnelli

Best Publications

  • The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

    R. Salgado;C. Denkert;S. Demaria;N. Sirtaine

  • Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group Part 2 TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

    Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

  • Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

    Sherene Loi;Damien Drubay;Sylvia Adams;Giancarlo Pruneri

  • Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research

    Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell

  • Resting and activated endothelial cells are increased in the peripheral blood of cancer patients

    Patrizia Mancuso;Alessandra Burlini;Giancarlo Pruneri;Aron Goldhirsch

  • Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations

    Larissa A. Korde;Jo Anne Zujewski;Leah Kamin;Sharon Hermes Giordano

  • Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.

    Viviana Galimberti;Bernard F Cole;Giuseppe Viale;Giuseppe Viale;Paolo Veronesi;Paolo Veronesi

  • Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

    Annarita Conconi;Giovanni Martinelli;Catherine Thiéblemont;Andrés J M Ferreri

  • Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment

    Marco Colleoni;Giuseppe Viale;David Zahrieh;Giancarlo Pruneri

  • Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

    Maria Vittoria Dieci;Nina Radosevic-Robin;Susan Fineberg;Gert Van den Eynden

  • Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

    Giuseppe Lo Russo;Massimo Moro;Michele Sommariva;Valeria Cancila

  • Angiogenesis in myelodysplastic syndromes.

    G Pruneri;F Bertolini;D Soligo;N Carboni

  • The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

    Stella Mook;Marjanka K. Schmidt;Giuseppe Viale;Giuseppe Viale;Giancarlo Pruneri;Giancarlo Pruneri

  • Predicting the Risk for Additional Axillary Metastases in Patients With Breast Carcinoma and Positive Sentinel Lymph Node Biopsy

    Giuseppe Viale;Eugenio Maiorano;Giancarlo Pruneri;Mauro G. Mastropasqua

  • Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group

    G Ryan;Giovanni Martinelli;M Kuper-Hommel;R Tsang

  • Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial

    Bernardo Bonanni;Matteo Puntoni;Massimiliano Cazzaniga;Giancarlo Pruneri

  • Genomic Characterization of Primary Invasive Lobular Breast Cancer

    Christine Desmedt;Gabriele Zoppoli;Gunes Gundem;Giancarlo Pruneri

  • Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.

    Giovanni Martinelli;Daniele Laszlo;Andrés J M Ferreri;Giancarlo Pruneri

  • ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)

    Shani Paluch-Shimon;Olivia Pagani;Ann H. Partridge;Omalkhair Abulkhair

  • Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

    Maria Vittoria Dieci;Nina Radosevic-Robin;Susan Fineberg;Gert van den Eynden

Frequent Co-Authors

Giuseppe Viale
Giuseppe Viale University of Milan
Giovanni Martinelli
Giovanni Martinelli University of Bologna
Francesco Bertolini
Francesco Bertolini European Institute of Oncology
Paolo Veronesi
Paolo Veronesi European Institute of Oncology
Antonino Neri
Antonino Neri University of Milan
Giuseppe Curigliano
Giuseppe Curigliano University of Milan
Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles
Vincenzo Bagnardi
Vincenzo Bagnardi University of Milano-Bicocca
Nicole Rotmensz
Nicole Rotmensz European Institute of Oncology
Patrick Maisonneuve
Patrick Maisonneuve European Institute of Oncology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative routes to a medical or healthcare career has never been more accessible, with a range of online degrees now available. For registered nurses looking to progress, there are accredited rn to bsn online without clinicals options, which let you advance your credentials without the need for additional clinical hours.

Ambitious nurses can also consider doctoral programs; some universities offer short dnp programs designed for fast-track completion, while others highlight the easiest dnp program reddit recommendations for those seeking a manageable workload alongside their professional duties.

For those aiming to start their healthcare journey quickly, the availability of accelerated lpn program paths means you can enter the workforce sooner with the foundational skills you need.

Each route varies in terms of requirements, duration, and intensity, but online options make it easier than ever to balance study with work or family commitments. Consider your personal and professional goals to choose the best pathway for your future in medicine or healthcare.

Best Scientists Citing Giancarlo Pruneri

Trending Scientists